Mississippi River, New Orleans, LA  抗組織胺的發展 History of Antihistamine 郭和昌 醫師 高雄長庚兒童過敏免疫風濕科 2010  Treatment of allergic rhin...
<ul><li>國立陽明大學醫學士 </li></ul><ul><li>長庚大學臨床醫學研究所博士班進修 </li></ul><ul><li>中華民國小兒科專科醫師 </li></ul><ul><li>中華民國免疫過敏專科醫師 </li></u...
台北地區學童氣喘盛行率
Heidelberg, Germany Antihistamine
Pathophysiology of allergic disorders KD Yang at al.  Clinical Immunology
Histamine Receptors  組織胺接受器的種類 種類 作用位置 反應 H 1 Receptor <ul><li>血管壁上的平滑肌 </li></ul><ul><li>血管的內皮細胞 </li></ul><ul><li>神經系統 <...
1937 1942 1979 1954 1996 1988 2001 口乾、眼花、拮抗  EPS  椎體外症候群 嗜睡 History of Antihistamines Anti-histaminic effect Anti-choliner...
各式各樣的抗組織胺  (1) Alkylamines Ethanolamine Ethylenediamine Chlorpheniramine Brompheniramine Tripolidine Diphenhydramine Clema...
各式各樣的抗組織胺  (2) Piperidine Others Phenothiazine Methdilazine Promethazine Loratadine Terfenadine Ebastine Mizolastine Astem...
各種抗組織胺的演變 Hydroxyzine 1954 Cetirizine 1987 Levocetirizine 2001 Terfenadine 1981 Fexofenadine 1996 Loratadine 1988 Deslorat...
從  cetirizine  到  levocetirizine ( 左旋異構體 ) <ul><li>Isomer:  同素異構物 </li></ul><ul><li>Enantiomer:  鏡像異構物 </li></ul><ul><li>R...
Racemic Mixtures ( 鏡像混合物 ) <ul><li>許多藥物即使成分相同,但是成分中都有同素異構物  ( 鏡像異構物、空間異構物 )  的存在。 </li></ul><ul><li>Cetirizine  是左旋與右旋異構物的...
Holliday Inn, New Orleans, LA Which one is useful?
The Nobel Prize in Chemistry 2001  For “the development of catalytic asymmetric synthesis” William S. Knowles  1/4 of the ...
東京 - 皇居二重橋 Optimal properties of antihistamines
Allergy  2006: 61: 1086–1096 理想的抗組織胺
理想的抗組織胺應該具有的特性 <ul><li>對  H 1  receptor  要有高度的親合力 </li></ul><ul><ul><li>與受體作用的強度要強  ( 不會在高濃度的組織胺下失去作用 ) </li></ul></ul><ul...
Levocetirizine 對於受器具有高度的選擇性 pKi 3 4 5 6 7 8 9 10 Low selectivity could lead to unwanted side effects  Inflamm Res.  2003 A...
Levocetirizine   對於受器具有良好的親合力 Effects on the histamine (10 -4  M) induced contraction  on the isolated guinea pig trachea ...
抗組織胺  PK-PD  的比較圖 Am J Med  2002;113(9A): 38S–46S. Fundam Clin Pharmacol  2004 (18): 399–411. Levocetirizine Desloratadine...
A new trend of souvenirs collection
美濃悠境 Allergic rhinitis
Allergy march
Pediatr Neonatol 2009;50(1):18−25 Prevalence of AR in Taiwan
Co-morbidity of AR Allergy 2006: 61: 656–664
Treatment of AR sneezing rhinorrhea nasal nasal eye obstruction itch symptoms H1-antihistamines oral +++ +++ 0 to + +++ ++...
<ul><li>Options (not in preferred order) </li></ul><ul><li>- oral or intranasal anti-H1  </li></ul><ul><li>- intranasal de...
<ul><li>Options (not in preferred order) </li></ul><ul><li>- oral or intranasal anti-H1  </li></ul><ul><li>- oral anti-H1 ...
<ul><li>Step-wise approach </li></ul><ul><li>-  intranasal CS as a first line treatment </li></ul><ul><li>- if major block...
Levocetirizine and desloratadine in EEU TM <ul><li>The EEU controls confounding variables through: </li></ul><ul><li>Stand...
Levocetirizine and desloratadine in EEU TM Evolution of Major Symptom Complex (MSC) score Int J Clin Pract . 2004 Feb;58(2...
Levocetirizine in persistent allergic rhinitis:  continuous or on-demand use ? <ul><li>The present open label study: 62 pa...
Clin Ther.  2009 May;31(5):921-44.  Indication of desloratadine, fenofenadine and levocetirizine
Levocetirizine for the treatment of AR and chronic idiopathic urticaria in adults and children.  Clin Ther . 2009 Aug;31(8...
Cost-effectiveness  Clin Ther . 2009 Aug;31(8):1664-87.
Central Park, NY
Central park, Kaohsiung Skin wheal
Is a common skin condition, affecting up to  20%  of individuals  at some time in their life. Name comes from the Latin  u...
<ul><li>不同因 同果 ! </li></ul><ul><li>PHYSICAL STIMULI </li></ul><ul><li>Dermographism, Pressure or Stretch, Cold, Heat, Sun ...
Histamine H 1 -Receptors and the Wheal and Flare Response H 1 -receptors on  blood vessels - local vasodilatation - local ...
Step-up tx for chronic urticaria Clin Exp Allergy.  2007;37(5)631-650. 6) Add or substitute other second-line agents   (ie...
Wheal response during 24 hours Ann Allergy Asthma Immunol . 2002 Feb;88(2):190-7. (n=18 crossover) 1600 1400 1200 1000 800...
Flare response during 24 hours 50’000 40’000 30’000 20’000 10’000 0 Placebo Ebastine (10 mg) Fexofenadine (180 mg) Loratad...
Wheal and flare response during 24 hours <ul><li>Levocetirizine was the  most potent  drug for inhibiting the histamine-in...
Levocetirizine in the treatment of chronic idiopathic urticaria British Journal of Dermatology  2006 154, 533–538 . Contro...
Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine. Br J Clin Pharmacol . 2008 F...
Comparison of the efficacy of levocetirizine and desloratadine in chronic idiopathic urticaria patients.  <ul><li>levoceti...
1/3 of acute childhood urticaria leading to patient hospitalization was related to  M pneumoniae  infection. Ann Allergy A...
Kapellbrucke, Luzern More than anti-histamine…
Allergy, Asthma & Clinical Immunology  2009,  5 :14 levocetirizine, but not desloratadine or placebo, significantly decrea...
4wks J Pharmacol Sci 2008  108, 149 – 156. IL-12Rβ1 ICAM1+ T cells helper/ inducer T cells effector helper /inducers cells
北海道 - 函館山 - 百萬夜景 Levocetirizine (Xyzal: 驅異樂 )
<ul><li>錠劑/ 5MG/Tab  本品為 Cetirizine 的異構物,且選擇性的抗組織胺作用。  治療項目:  〔署核〕治療 成人 因季節性 過敏性鼻炎 及  長年性過敏性鼻炎所引起的各種過敏徵狀。  用法用量:  1. 服用時以水...
注意事項 <ul><li>1. 六歲以下的孩童不建議使用本藥 。服用酒類也需特別小心。  </li></ul><ul><li>2. 若具有 對 galactose 無耐受力 ,或 Lapp lactase 缺乏,或有  glucose-gala...
Manila Bay
逆境中生存
What is his need ? Vena Periactin Clarinase desloratadine Allergra Xyzal  Or Just clothes ! Manila bay
Thanks a lot! 雅典學院 :Academy, 8000pc puzzle 不同的抗組織胺 特性、親合力、藥物動力學特性、藥效 都有很大的差異 選擇最合適的抗組織胺 !
Upcoming SlideShare
Loading in …5
×

Antihistamine introduction by Ho-Chang Kuo, MD (郭和昌醫師)

4,385 views
4,243 views

Published on

An introduction of antihistamine and the history of it. New product of long acting anti-histamine (xyzal)

0 Comments
3 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
4,385
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
0
Comments
0
Likes
3
Embeds 0
No embeds

No notes for slide
  • Adhesion Molecules-Complementary cell surface molecules expressed on leukocytes, endothelial and structural cells that allow leukocyte adherence
  • The history of antihistamines began in 1937 with the discovery by Anne-Marie Staub and Daniel Bovet of the first antihistaminic compound, for which Bovet was awarded the Nobel prize. This discovery opened the door for many pharmaceutical companies to develop antihistaminic drugs and soon after a number of drugs with antihistaminic properties – the first generation antihistamines - appeared on the market. While exerting good antihistaminic properties, the first generation antihistamines were plagued by important unwanted side effects of which the major ones were anti-cholinergic effects (dry mouth) and sedation due to the penetration to the CNS. Consequently, an effort was made to develop compounds free of these unwanted effects. This resulted in the development of the second generation H 1 -antagonists, most of them metabolites of the first generation antihistamines. Terfenadine was the first of these new compounds to be launched onto the market. While, indeed, sedation and anti-cholinergic side effects were no longer attributes of this compound, its use was associated with important heart problems in a limited number of patients which lead to its withdrawal from the market in most of the countries. Astemizole, the second of the second generation antihistamines had the same problems and had the same fate as terfenadine. The new antihistamines that followed: cetirizine (1988), loratadine and fexofenadine were free not only of anti-cholinergic and CNS side effects but also from cardiotoxicity. However, the research did not stop here and these second generation compounds were followed by a newer drugs of which the most recently introduced is levocetirizine (2001)
  • The older antihistaminic agent terfenadine was found to metabolize into the related carboxylic acid , fexofenadine. Fexofenadine was found to retain all of the biological activity of its parent while giving fewer adverse reactions in patients, so terfenadine was replaced in the market by its metabolite . [5] Fexofenadine was originally synthesized in 1993 by Massachusetts -based biotechnology company Sepracor , which then sold the development rights to Hoechst Marion Roussel (now part of Sanofi -Aventis ), and was later approved by the Food and Drug Administration (FDA) in 1996. AMRI holds the patents to the intermediates and production of fexofenadine HCl along with Roussel. Since that time, it has achieved blockbuster drug status with global sales of $1.87B USD in 2004 (with $1.49B USD coming from the United States ). AMRI received royalty payments from Aventis that enabled the growth of AMRI. Desloratadine is a drug used to treat allergies . It is marketed under several trade names such as NeoClarityn , Claramax , Clarinex and Aerius . It is an active metabolite of loratadine , which is also on the market.
  • For more than 50 years of history of antihistamines real progresses hav – and this is where it ended!! Ebastine (trade names Kestine , Evastin , Ebastel , Aleva ) is a non-sedating H1 antihistamine . It does not penetrate the blood-brain barrier and thus allows an effective block of the H1 receptor in peripheral tissue without a central side effect, i.e not causing sedation or drowsiness. The basic patent for ebasine in Europe is EP-B-134124. It is often provided in micronised form, due to poor water solubility. Chewable, non-chewable, and syrup forms of cetirizine are similarly absorbed rapidly and effectively, with absorbed food minutely affecting the absorption rate which yields a peak serum level one hour after administration; [3] in a study of healthy volunteers prescribed 10mg tablets, once daily for 10 days, a mean peak serum level of 311 ng/mL was observed. [4] The metabolic effects of cetirizine are long acting; remaining in the system for a maximum of 21 hours before being excreted, the average elimination half-life is 8 hours. [3] [4] 70% of the drug is excreted or eliminated by kidney function within 72 hours, and 10% is removed through urine or excrement; [3] [4] of which half is observed as unchanged cetirizine compound. [3] [4] Like many other antihistamine medications, cetirizine is commonly prescribed in combination with pseudoephedrine hydrochloride , a decongestant . These combinations are marketed using the same brand name as the cetirizine with a &amp;quot;-D&amp;quot; suffix ( Zyrtec-D , Virlix-D , etc.) Additionally, cetirizine HCl not sold in combination with pseudoephedrine, is commonly known and marketed in the United States under the brand name, &amp;quot;Zyrtec.&amp;quot; Formerly only available by a prescription, both Zyrtec and Zyrtec-D are currently available over the counter in the United States. In the Philippines, a leading cetirizine is Aforvir.
  • Amphetamine (Benzedrine; street amphetamine is also racemic) and dextroamphetamine (Dexedrine) Bupivacaine (Marcain) and levobupivacaine (Chirocaine) Cetirizine (Zyrtec / Reactine) and levocetirizine (Xyzal) Citalopram (Celexa / Cipramil) and escitalopram (Lexapro / Cipralex) Methylphenidate (Ritalin) and dexmethylphenidate (Focalin) Modafinil (Provigil) and armodafinil (Nuvigil) Ofloxacin (Floxin) and levofloxacin (Levaquin) Omeprazole (Prilosec) and esomeprazole (Nexium) Salbutamol (Ventolin) and levalbuterol (Xopenex) Zopiclone (Imovane) and eszopiclone (Lunesta)
  • (only one enantiomer can actively exert a certain function while the other one is inactive; just like the human beings who, in general, have a dominant hand either the right or the left one). As consequence, even if enantiomers are characterized by the same physical and chemical properties, they can have different biological functions. Due to the stereoselectivity of the biological systems, for many drugs existing in two enantiomeric forms only one of the enantiomers is responsible for the therapeutic activities of the respective drug while the other one is inactive. Therefore, separating the active enantiomer of a drug from the inactive one becomes important and the recommendation of FDA is that drug molecules having stereocenters should be given to patients only in the active enantiomeric form and not as a racemic mixture. Some drug molecules are chiral, and the enantiomers have different effects on biological entities. They can be sold as one enantiomer or as a racemic mixture. Examples include Thalidomide , Ibuprofen , and Salbutamol . Adderall is a mixture of several different enantiomers. A single amphetamine dose combines the neutral sulfate salts of dextroamphetamine and amphetamine, with the dextro isomer of amphetamine saccharate and D/L-amphetamine aspartate monohydrate. The prescription analgesic tramadol is also a racemate. In some cases (e.g., Ibuprofen and Thalidomide), the enantiomers are interconverted in vivo . This means that preparing a pure enantiomer for medication is largely pointless. In cases like Salbutamol and Thalidomide, the inactive isomer may be harmful. Methamphetamine is available by prescription under the brand name Desoxyn . The active component of Desoxyn is dextro-methamphetamine hydrochloride. This is the right-hand isomer of methamphetamine. The left-handed isomer of methamphetamine, levo-methamphetamine, is less centrally-acting and more peripherally-acting; therefore a racemic mixture of dextro/levo-methamphetamine is not used in current medical practice. In the past, due to different levels of restrictions on precursor chemicals and lack of knowledge by those preparing the final product, racemic methamphetamine was produced and sold on the black market. Newer techniques typically use asymmetric synthesis methods, and yield a majority of D-methamphetamine and relatively little L-methamphetamine. In the chemical name, a D/L- prefix indicates that both the levo &amp; dextro isomers are contained in the product to some unspecified degree. Whereas a DL- prefix with no slash mark indicates that both levo &amp; dextro isomers of the molecule are present in an equal 1:1 ratio, with 50% of each.
  • Until 2001 the separation of the chiral molecules at an economical industrial level was impossible. However in 2001 scientific progress in the domains of chemistry and technology allowed UCB to go one step further in the process of drug development. In 2001 the Nobel prize in chemistry was given for new developments in the field of chiral chemistry. Due to their work, the separation of chiral molecules became possible and UCB was finally able to separate levocetirizine from dextrocetirizine and to develop Xyzal ®.
  • ‘ What is expected from a good antihistamine?’ Pharmacodynamic attributes are: high affinity for the H1 receptor meaning that it’s binding is strong and persistent. high selectivity for the H1 receptor, meaning it binds to the histamine receptor, but not to other type of receptors (mainly muscarinic ones), and so it is free from side effects.
  • Affinity to the H1 receptor essential in exerting the antihistaminic activity. Selectivity for the H 1 histamine receptor is also imperative in order to reduce the unwanted side effects which characterized the first generation antihistamines. In a study comparing the selectivity and the affinity of levocetirizine with that of loratadine, desloratadine, fexofenadine it was shown that levocetirizine has the higher selectivity for H1 receptor compared with any of the other antihistamine studied. Fexofenadine also showed almost the same level of affinity and selectivity for H1 receptor as levocetirizine. While desloratadine showed the highest affinity for the H 1 receptor, it also had a high affinity for all 5 types of muscarinic receptors, which suggests that its antihistaminic activity of could be accompanied by anticholinergic side effects.
  • Evaluated the ability of equivalent concentrations of the three compounds to induce relaxation of the guinea pig trachea in which contraction was previously provoked by stimulation with histamine. Three increasing concentrations of histamine were used (10 -6 , 10 -5 , 10 –4 ) and the antihistaminic effect of drugs was evaluated for each histamine concentration. At high concentrations of histamine (10-4 M ) the antihistaminic effect of levocetirizine was more potent than that of cetirizine as it had the ability to inhibit completely the histamine induced contraction while cetirizine reached only 80% inhibition at 120 minute. Also at the same histamine concentration the antihistaminic effect of dextrocetirizine was very weak, matching closely the placebo response.
  • When comparing other pharmacokinetic characteristics of levocetirizine with that of the major second generation antihistamines currently in use, it appears that levocetirizine has the fastest absorption from the gastrointestinalfastest &amp; is the compound excreted unchanged in the urine in the highest proportion , has the fastest onset of action and a duration of action of at least 24 hours.
  • The Mechanisms of Urticaria The title diagram illustrates that the mast cell is the primary cause of Urticaria Reference : UCB Training Manual Chapter 3 Allergy and Allergic Cascade 3.3.5 Urticaria Braunwald, Eugene; Fauci, Anthony; Kasper, Dennis; Hauser, Stephen; Longo, Dan; Jameson, Larry, ed (2001). Harrison&apos;s principles of internal medicine (15th Edition ed.). New York: McGraw-Hill. pp. 95 &amp; 306. ISBN 0070072728 .
  • The Mechanisms of Urticaria The title diagram illustrates that the mast cell is the primary cause of Urticaria Reference : UCB Xyzal Training Manual Chapter 3 Allergy and Allergic Cascade 3.3.5 Urticaria
  • Histamine H1-Receptors and the Wheal and Flare Response Diagram thirteen summarises the role of histamine receptors in the skin. Number one indicates that histamine H1-receptors are on the local blood vessels which will cause local vasodilatation and local oedema. Number two indicates that histamine H1-receptors are also present on the nerves which initiate pruritus and the surrounding neurogenic flare. Reference : UCB Xyzal Training Manual
  • Reference : UCB Xyzal Training Manual
  • Antihistamine introduction by Ho-Chang Kuo, MD (郭和昌醫師)

    1. 1. Mississippi River, New Orleans, LA 抗組織胺的發展 History of Antihistamine 郭和昌 醫師 高雄長庚兒童過敏免疫風濕科 2010 Treatment of allergic rhinitis & histamine induced wheal
    2. 2. <ul><li>國立陽明大學醫學士 </li></ul><ul><li>長庚大學臨床醫學研究所博士班進修 </li></ul><ul><li>中華民國小兒科專科醫師 </li></ul><ul><li>中華民國免疫過敏專科醫師 </li></ul><ul><li>台灣兒童過敏氣喘暨免疫學會專科醫師 </li></ul><ul><li>美國過敏氣喘免疫學會 (AAAAI) 會員 </li></ul><ul><li>歐洲過敏氣喘及臨床免疫學會 (EAACI) 會員 </li></ul><ul><li>亞洲兒科醫學研究學會 (ASPR) 會員 </li></ul><ul><li>高雄長庚助理教授級主治醫師 (2010~) </li></ul><ul><li>長庚大學兼任講師 (2009~) </li></ul><ul><li>教育部審訂講師 (2009~) </li></ul><ul><li>川崎症專屬部落格 </li></ul><ul><ul><li>http://tw.myblog.yahoo.com/erickuo48 </li></ul></ul>郭和昌 醫師 Rotenberg, Germany
    3. 3. 台北地區學童氣喘盛行率
    4. 4. Heidelberg, Germany Antihistamine
    5. 5. Pathophysiology of allergic disorders KD Yang at al. Clinical Immunology
    6. 6. Histamine Receptors 組織胺接受器的種類 種類 作用位置 反應 H 1 Receptor <ul><li>血管壁上的平滑肌 </li></ul><ul><li>血管的內皮細胞 </li></ul><ul><li>神經系統 </li></ul><ul><li>黏液線體 </li></ul><ul><li>平滑肌 </li></ul><ul><li>血管擴張導致黏膜下或皮下水腫 </li></ul><ul><li>更多趨化物質的釋出 </li></ul><ul><li>局部的刺激與癢痛 </li></ul><ul><li>黏液的分泌增加 </li></ul><ul><li>平滑肌收縮 </li></ul><ul><li>頭暈與動暈症 </li></ul>H 2 Receptor <ul><li>胃壁細胞 parietal cell </li></ul><ul><li>心肌細胞 </li></ul><ul><li>刺激胃酸的分泌 </li></ul><ul><li>增加心房控制的心跳速率 </li></ul>H 3 Receptor <ul><li>中樞神經系統 </li></ul><ul><li>抑制神經傳導物質的釋放,例如 : histamine, acetylcholine, norepinephrine, serotonin </li></ul><ul><li>嗜睡 </li></ul>H 4 Receptor <ul><li>骨髓、嗜鹼性球 </li></ul><ul><li>胸線、脾臟、腸道 </li></ul><ul><li>作用不明,似乎與免疫系統的作用有關 </li></ul>
    7. 7. 1937 1942 1979 1954 1996 1988 2001 口乾、眼花、拮抗 EPS 椎體外症候群 嗜睡 History of Antihistamines Anti-histaminic effect Anti-cholinergic effect 抗乙醯膽鹼 H 3 Sedative effect 鎮定作用 H 3 Staub Bovet phenbenzamine chlorpheniramine Hydroxyzine levocetirizine terfenadine fexofenadine astemizole cetirizine loratadine desloratadine
    8. 8. 各式各樣的抗組織胺 (1) Alkylamines Ethanolamine Ethylenediamine Chlorpheniramine Brompheniramine Tripolidine Diphenhydramine Clemastine Antazoline Tripenelamine Acrivastine CLASS OLD 1st GENERATION 2nd NEW GENERATION H 1 selective
    9. 9. 各式各樣的抗組織胺 (2) Piperidine Others Phenothiazine Methdilazine Promethazine Loratadine Terfenadine Ebastine Mizolastine Astemizole Ketotifen Azelastine Desloratadine Fexofenadine Tecastemizole Azatadine CLASS OLD 1st GENERATION 2nd NEW GENERATION Newer GENERATION Piperazine Levocetirizine Cetirizine Hydroxyzine
    10. 10. 各種抗組織胺的演變 Hydroxyzine 1954 Cetirizine 1987 Levocetirizine 2001 Terfenadine 1981 Fexofenadine 1996 Loratadine 1988 Desloratadine 2001 Ebastine 1990 Carebastine ? Parent drug Metabolite Eutomer
    11. 11. 從 cetirizine 到 levocetirizine ( 左旋異構體 ) <ul><li>Isomer: 同素異構物 </li></ul><ul><li>Enantiomer: 鏡像異構物 </li></ul><ul><li>Racemate: 鏡像異構物的混合物 </li></ul>
    12. 12. Racemic Mixtures ( 鏡像混合物 ) <ul><li>許多藥物即使成分相同,但是成分中都有同素異構物 ( 鏡像異構物、空間異構物 ) 的存在。 </li></ul><ul><li>Cetirizine 是左旋與右旋異構物的混合物,但是 Levocetirizine 是單純的 左旋異構物 。 </li></ul><ul><li>生化系統的作用就像鑰匙與門鎖,有高度的專一性,即使化學成分相同,也只有特定專一的一種異構物可以發揮作用。 </li></ul><ul><li>就像我們不能將右手 (dextro-) 放入左手 (levo-) 的棒球手套中 </li></ul>
    13. 13. Holliday Inn, New Orleans, LA Which one is useful?
    14. 14. The Nobel Prize in Chemistry 2001 For “the development of catalytic asymmetric synthesis” William S. Knowles 1/4 of the prize St. Louis, MO, USA b. 1917 Ryoji Noyori 1/4 of the prize Nagoya University Nagoya, Japan b. 1938 得獎原因 : 鏡像異構物催化氫化反應 K. Barry Sharpless 1/2 of the prize The Scripps Research Institute La Jolla, CA, USA b. 1941 得獎原因 : 鏡像異構物催化氧化反應
    15. 15. 東京 - 皇居二重橋 Optimal properties of antihistamines
    16. 16. Allergy 2006: 61: 1086–1096 理想的抗組織胺
    17. 17. 理想的抗組織胺應該具有的特性 <ul><li>對 H 1 receptor 要有高度的親合力 </li></ul><ul><ul><li>與受體作用的強度要強 ( 不會在高濃度的組織胺下失去作用 ) </li></ul></ul><ul><ul><li>與受體作用的時間要長 ( 體內才有時間清除過多的組織胺 ) </li></ul></ul><ul><ul><li>Receptor occupancy is more representative of antihistamine potency. </li></ul></ul><ul><li>高度的選擇性 </li></ul><ul><ul><li>不會與 H 2 、 H 3 、 H 4 的受器結合 ( 減少副作用 ) </li></ul></ul><ul><li>減少副作用 </li></ul>Allergy 2006: 61: 1086–1096
    18. 18. Levocetirizine 對於受器具有高度的選擇性 pKi 3 4 5 6 7 8 9 10 Low selectivity could lead to unwanted side effects Inflamm Res. 2003 Apr;52 Suppl 1:S49-50 H1 M2 M5 M3 M4 M1 Levocetirizine Loratadine Desloratadine Fexofenadine < 4.0 Highly selective
    19. 19. Levocetirizine 對於受器具有良好的親合力 Effects on the histamine (10 -4 M) induced contraction on the isolated guinea pig trachea Pharmacology . 2007;79(2):104-13. Levocetirizine inhibited completely the contractions whereas cetirizine reached only 80% inhibition of the contraction after 120 minutes. Control (DMSO 0.1%) Cetirizine 2.10 -6 M Levocetirizine 10 -6 M Dextrocetirizine 10 -6 M 10 20 30 40 50 60 70 80 90 100 110 120 0 10 20 30 40 50 60 70 80 90 100 110 Time (min) E max (%)
    20. 20. 抗組織胺 PK-PD 的比較圖 Am J Med 2002;113(9A): 38S–46S. Fundam Clin Pharmacol 2004 (18): 399–411. Levocetirizine Desloratadine Fexofenadine Cetirizine Absorption (t max; hours) 0.8 ±0.5 3.0 1.0 - 3.0 1.0 ±0.5 Plasma t ½ (hours) 7 ±1.5 27 14.4 6.5 - 10 Distribution (Vd; l/kg) 0.33 49 5.8 ± 0.7 0.56 Protein binding (%) 96 - 60 - 70 93 Excretion in urine/feces (%) 85/13 41/47 12/80 60/0 Onset of action (hours) 0.5 3 1 - 2 0.7 Duration of action (hours) > 24 > 24 24 > 24
    21. 21. A new trend of souvenirs collection
    22. 22. 美濃悠境 Allergic rhinitis
    23. 23. Allergy march
    24. 24. Pediatr Neonatol 2009;50(1):18−25 Prevalence of AR in Taiwan
    25. 25. Co-morbidity of AR Allergy 2006: 61: 656–664
    26. 26. Treatment of AR sneezing rhinorrhea nasal nasal eye obstruction itch symptoms H1-antihistamines oral +++ +++ 0 to + +++ ++ intranasal ++ +++ + ++ 0 intraocular 0 0 0 0 +++ Intranasal CS +++ +++ ++ ++ + Chromones intranasal + + + + 0 intraocular 0 0 0 0 ++ Decongestants intranasal 0 0 ++ 0 0 oral 0 0 + 0 0 Anti-cholinergics 0 +++ 0 0 0 Anti-leukotrienes + ++ ++ ? ++
    27. 27. <ul><li>Options (not in preferred order) </li></ul><ul><li>- oral or intranasal anti-H1 </li></ul><ul><li>- intranasal decongestants (> 6 y/o) </li></ul><ul><li>- oral decongestants (not in children) </li></ul>Mild intermittent rhinitis ARIA
    28. 28. <ul><li>Options (not in preferred order) </li></ul><ul><li>- oral or intranasal anti-H1 </li></ul><ul><li>- oral anti-H1 + decongestant </li></ul><ul><li>- intranasal CS </li></ul><ul><li>- chromolyn </li></ul><ul><li>Patient should be re-assessed after 2-4 wks </li></ul>Moderate-severe intermittent rhinitis Mild persistent rhinitis (ARIA)
    29. 29. <ul><li>Step-wise approach </li></ul><ul><li>- intranasal CS as a first line treatment </li></ul><ul><li>- if major blockage: add short course of oral CS or decongestant </li></ul><ul><li>Re-assess after 2-4 weeks </li></ul><ul><li>- if symptoms present add: </li></ul><ul><li>- oral anti-H1 (± decongestants) </li></ul><ul><li>- ipratropium </li></ul>Moderate-severe persistent rhinitis ARIA
    30. 30. Levocetirizine and desloratadine in EEU TM <ul><li>The EEU controls confounding variables through: </li></ul><ul><li>Standardized pollen type , standardized concentrations </li></ul><ul><li>Removal of “wild” allergens by filtration </li></ul><ul><li>Standardized scoring of symptom severity levels and of medical efficacy </li></ul>Int J Clin Pract . 2004 Feb;58(2):109-18. Environmental Exposure Unit (EEU)
    31. 31. Levocetirizine and desloratadine in EEU TM Evolution of Major Symptom Complex (MSC) score Int J Clin Pract . 2004 Feb;58(2):109-18. * * 10.0 8.0 9.0 6.0 4.0 7.0 5.0 3.0 2.0 1.0 0.0 -1.0 -2.0 -3.0 0 1 2 3 Drug intake 4 5 23 24 25 26 * † * † * † * † * † * † * † * * * * † * † * † * * * * 27 28 * † * † * † * † * † * † * † * * * * † Drug intake Desloratadine 5 mg Placebo Levocetirizine 5 mg Period I Reduction from baseline MSC Score (LS Mean) Period II Period III Hours after first drug intake * p < 0.001 vs placebo ° p < 0.05 vs placebo p < 0.05 vs desloratadine † (n=373)
    32. 32. Levocetirizine in persistent allergic rhinitis: continuous or on-demand use ? <ul><li>The present open label study: 62 patients </li></ul><ul><li>indicates that levocetirizine 5 mg reliably controls persistent rhinitis over a period of 6 months , and shows a trend to be more effective in controlling the symptoms of rhinitis, improving QOL and decreasing nasal inflammation, </li></ul><ul><li>when administered as long-term continuous therapy rather than as on-demand therapy . </li></ul>Curr Med Res Opin . 2008 Oct;24(10):2829-39.
    33. 33. Clin Ther. 2009 May;31(5):921-44. Indication of desloratadine, fenofenadine and levocetirizine
    34. 34. Levocetirizine for the treatment of AR and chronic idiopathic urticaria in adults and children. Clin Ther . 2009 Aug;31(8):1664-87.
    35. 35. Cost-effectiveness Clin Ther . 2009 Aug;31(8):1664-87.
    36. 36. Central Park, NY
    37. 37. Central park, Kaohsiung Skin wheal
    38. 38. Is a common skin condition, affecting up to 20% of individuals at some time in their life. Name comes from the Latin urtica which means sting ( 刺 , 螫 , 叮 ) . Clinical Features: Transient nature of wheals surrounded by an erythematous flare and itch. It has the ability to change localization within 24 hours. Urticaria <ul><li>WHEALS </li></ul><ul><li>a firm, elevated swelling of the skin known in medical terminology as a papule 1 . </li></ul><ul><li>generally pale red in color, although color can also be deep red or purple; may be round, oval or irregular in shape and are usually rounded or flat topped </li></ul><ul><li>FLARES </li></ul><ul><li>reddening of the skin spreading outward from a focus of infection or irritation </li></ul>
    39. 39. <ul><li>不同因 同果 ! </li></ul><ul><li>PHYSICAL STIMULI </li></ul><ul><li>Dermographism, Pressure or Stretch, Cold, Heat, Sun </li></ul><ul><li>CHEMICAL STIMULI </li></ul><ul><li>Food, Food additives, Drugs, Toxins of plants and Insects </li></ul><ul><li>INFECTION </li></ul><ul><li>Viral, Bacterial, Parasitic </li></ul><ul><li>Mycoplasma Pneumoniae </li></ul>Causes of urticaria
    40. 40. Histamine H 1 -Receptors and the Wheal and Flare Response H 1 -receptors on blood vessels - local vasodilatation - local oedema (wheal) H 1 -receptors on nerves - itching (pruritus) - surrounding reddening (flare) 1 2 1 2
    41. 41. Step-up tx for chronic urticaria Clin Exp Allergy. 2007;37(5)631-650. 6) Add or substitute other second-line agents (ie, cyclosporin or a low-dose corticosteroid*) 5) Consider adding or substituting with second- line agent (ie, anti-leukotriene) 4) Consider sedating antihistamine at night 3) Add second non-sedating H 1 antihistamine (regular or as required) 2) Higher dose of H 1 antihistamine 1) Standard dose of non-sedating H 1 antihistamine * Low-dose daily corticosteroid (5–10 mg/day) or low-dose alternative day corticosteroid (15–20 mg alt day) could be considered. Treatment should be stepped down once control is achieved Recommendations of the British Society for Allergy and Clinical Immunology Identification of Triggers Education and Avoidance of Triggers
    42. 42. Wheal response during 24 hours Ann Allergy Asthma Immunol . 2002 Feb;88(2):190-7. (n=18 crossover) 1600 1400 1200 1000 800 600 400 200 0 Placebo Ebastine (10 mg) Fexofenadine (180 mg) Loratadine (10 mg) Levocetirizine (5 mg) Mizolastine (10 mg) mm 2 .h (n=18 crossover)
    43. 43. Flare response during 24 hours 50’000 40’000 30’000 20’000 10’000 0 Placebo Ebastine (10 mg) Fexofenadine (180 mg) Loratadine (10 mg) mm 2 .h (n=18 crossover) Ann Allergy Asthma Immunol . 2002 Feb;88(2):190-7. Levocetirizine (5 mg) Mizolastine (10 mg)
    44. 44. Wheal and flare response during 24 hours <ul><li>Levocetirizine was the most potent drug for inhibiting the histamine-induced wheal and flare areas </li></ul><ul><li>Levocetirizine gave more than 95% inhibition of the wheal response in all subjects </li></ul><ul><li>Levocetirizine showed rapid onset of wheal and flare inhibition </li></ul><ul><li>Levocetirizine showed better consistency of the anti-H1 activity (all subjects respond more similarly to that treatment) </li></ul>Ann Allergy Asthma Immunol . 2002 Feb;88(2):190-7.
    45. 45. Levocetirizine in the treatment of chronic idiopathic urticaria British Journal of Dermatology 2006 154, 533–538 . Control levocetirizine
    46. 46. Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine. Br J Clin Pharmacol . 2008 Feb;65(2):172-9.
    47. 47. Comparison of the efficacy of levocetirizine and desloratadine in chronic idiopathic urticaria patients. <ul><li>levocetirizine increased the patients' global satisfaction after one and 4 weeks compared with desloratadine. </li></ul><ul><li>Safety and tolerability were similar in both groups . </li></ul><ul><li>CONCLUSIONS: Levocetirizine 5 mg was significantly more efficacious than desloratadine 5 mg in the treatment of CIU symptoms. </li></ul>Allergy . 2009 Apr;64(4):596-604.
    48. 48. 1/3 of acute childhood urticaria leading to patient hospitalization was related to M pneumoniae infection. Ann Allergy Asthma Immunol. 2009 Aug;103(2):134-9.
    49. 49. Kapellbrucke, Luzern More than anti-histamine…
    50. 50. Allergy, Asthma & Clinical Immunology 2009, 5 :14 levocetirizine, but not desloratadine or placebo, significantly decreased the number of eosinophils, neutrophils and IL-8 levels in nasal lavage samples during the pollen season while treatment with either antihistamine Significantly reduced IL-4 levels .
    51. 51. 4wks J Pharmacol Sci 2008 108, 149 – 156. IL-12Rβ1 ICAM1+ T cells helper/ inducer T cells effector helper /inducers cells
    52. 52. 北海道 - 函館山 - 百萬夜景 Levocetirizine (Xyzal: 驅異樂 )
    53. 53. <ul><li>錠劑/ 5MG/Tab 本品為 Cetirizine 的異構物,且選擇性的抗組織胺作用。 治療項目: 〔署核〕治療 成人 因季節性 過敏性鼻炎 及 長年性過敏性鼻炎所引起的各種過敏徵狀。 用法用量: 1. 服用時以水伴服吞入,飯前或飯後均可。建議每日單次服用。 </li></ul><ul><li>2. 成人及十二歲以上青少年:建議每日劑量為 5 公絲。 </li></ul><ul><li>3. 老年患者: 具有腎功能 障礙 的老年患者,需調整其劑量 。 請參考下述有關腎功能障礙者的用量。 </li></ul><ul><li>4. 六歲至十二歲的孩童:建議每日劑量為 5 公絲。 六歲以下 孩童不建議使用。 </li></ul><ul><li>5. 腎功能障礙患者:此類病患的服藥間隔應視其腎功能的 狀況而做調整。但先前必須先測得患者的肌酸酐廓清率。 </li></ul><ul><li>6. 肝功能障礙者:不需要調整劑量。但若同時具肝功能障礙及 腎功能障礙,則需調整劑量。 7. 使用期間:依個體差異,患者使用本藥的時間亦有長短。 乾草熱 (hayfever) : 約三至六星期:臨床有使用 cetirizine (levocetirizine 的異構物 ) 達一年的經驗。 </li></ul>Xyzal— 驅異樂 From: 國家網路藥典
    54. 54. 注意事項 <ul><li>1. 六歲以下的孩童不建議使用本藥 。服用酒類也需特別小心。 </li></ul><ul><li>2. 若具有 對 galactose 無耐受力 ,或 Lapp lactase 缺乏,或有 glucose-galactose 吸收障礙等遺傳疾病,則禁用本藥。 </li></ul><ul><li>3. 動物試驗顯示 levocetirizine 未有直接或間接對懷孕者、 生長中的胚胎,及出生後的胎兒造成傷害。若用於懷孕婦女時, 應非常小心。 </li></ul><ul><li>4.Levocetirizine 會滲入乳汁,因此 不建議授乳婦使用本藥 。 除非預期對母體的利益大於對嬰兒的理論危險性時,始列入考量。 </li></ul><ul><li>5. 若預期開車、從事具有危險性的活動、或操作機械時,必須不得超過建議劑量,且要考量患者對本藥的反應。對於較敏感的病患同時 服用酒精類或中樞神經抑制劑,則可能導致加成性的警覺性降低 及執行障礙。 </li></ul><ul><li>6. 過量:若服用過量時,成人會有嗜睡的現象,孩童則會先興奮不安,而後伴隨睏倦。對於 levocetirizine 過量 並無特殊解毒劑 。 </li></ul>From: 國家網路藥典
    55. 55. Manila Bay
    56. 56. 逆境中生存
    57. 57. What is his need ? Vena Periactin Clarinase desloratadine Allergra Xyzal Or Just clothes ! Manila bay
    58. 58. Thanks a lot! 雅典學院 :Academy, 8000pc puzzle 不同的抗組織胺 特性、親合力、藥物動力學特性、藥效 都有很大的差異 選擇最合適的抗組織胺 !

    ×